We can’t show the full text here under this license. Use the link below to read it at the source.
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
Comparing the Cost of Weekly Semaglutide, Exenatide, and Dulaglutide for Reaching Blood Sugar and Weight Loss Goals in the USA
AI simplified
Abstract
Once-weekly semaglutide 0.5 mg and 1.0 mg were most effective at achieving endpoints for glycemic control and weight loss.
- Patients treated with once-weekly semaglutide reached < 7.0%, HbA1c < 7.0% without hypoglycemia or weight gain, and achieved a ≥ 1.0% HbA1c reduction with ≥ 5.0% weight loss more effectively than those on exenatide ER and dulaglutide.
- The efficacy-to-cost ratios for semaglutide 0.5 mg and 1.0 mg were superior to all comparators when assessing the endpoint of HbA1c < 7.0%.
- Semaglutide also demonstrated better cost-efficiency in achieving composite endpoints that included weight loss and hypoglycemia avoidance.
AI simplified
Key numbers
9515 USD
Annual Treatment Cost
Estimated annual cost for once-weekly semaglutide 0.5 mg or 1.0 mg.
62%*
Efficacy Rate
Proportion of patients reaching target in SUSTAIN 3 trial.
65% †
Efficacy Rate
Proportion of patients reaching target in SUSTAIN 7 trial.